Cyclerion Therapeutics Inc (CYCN) Actualités

Form 8-K - Current report

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Regina Graul, Ph.D., Promoted to Chief Executive Officer

CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Cyclerion Appoints Regina Graul, Ph.D., as President

– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience...